Austar Lifesciences Ends Relocation Agreement

Austar Lifesciences Ltd. (HK:6118) has released an update.

Austar Lifesciences Ltd. has announced the termination of its Relocation Compensation Agreement with the Urban Industrial Park Management Committee, citing changing circumstances. The company has already relocated its facilities to a new manufacturing center in Shanghai, which began operations in the first half of 2023. The board reassures investors that this termination will not adversely affect the company’s business or financial standing.

For further insights into HK:6118 stock, check out TipRanks’ Stock Analysis page.